Ibrance (Tablets)(palbociclib)
Ibrance 75 MG Oral Tablet
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
Coverage Restrictions
Find Restrictions and Step Therapies for Ibrance (Tablets)
drug label
Ibrance (Tablets) Prescribing Information
samples
Request Ibrance (Tablets) Samples
pharmacy
Ibrance (Tablets) Preferred Pharmacy
Financial Assistance
Financial Assistance Programs
Ibrance (Tablets) retails for $15,078 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Ibrance (Tablets) for significantly less. Review the program information below to determine what program can offer your patient the most benefits.Copay Card Program$0 Copay
Available for
commercial
Program Details
- $25000 Annual Cap
Forms
Foundation ProgramFirst dose for $0
Available for
medicare
uninsured
Eligibility requirements
- Uninsured
- Medicare Part D
- Household annual adjusted gross income <= 500% FPL.
Forms
patient education
Ibrance (Tablets) Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Ibrance (Tablets) FAQs
What is the risk of IBRANCE during pregnancy?Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of palbociclib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at maternal exposures that were ≥4 times the human clinical exposure based on AUC. Pregnant women should be advised of the potential risk to a fetus.
What is the estimated background risk of major birth defects and miscarriage for IBRANCE?The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.
Is it safe to breastfeed while taking IBRANCE?There is no information regarding the presence of palbociclib in human milk, its effects on milk production, or the breastfed infant. Because of the potential for serious adverse reactions in breastfed infants from IBRANCE, advise a lactating woman not to breastfeed during treatment with IBRANCE and for 3 weeks after the last dose.
Should females of reproductive potential use contraception during treatment with IBRANCE?Females of reproductive potential should use effective contraception during treatment with IBRANCE and for at least 3 weeks after the last dose, as IBRANCE can cause fetal harm when administered to a pregnant woman.
Should male patients with female partners of reproductive potential use contraception during treatment with IBRANCE?Male patients with female partners of reproductive potential should use effective contraception during treatment with IBRANCE and for 3 months after the last dose, as IBRANCE may cause genotoxicity.
Can IBRANCE impair fertility in males of reproductive potential?Based on animal studies, IBRANCE may impair fertility in males of reproductive potential.
Is IBRANCE safe for pediatric use?The safety and efficacy of IBRANCE in pediatric patients have not been studied.
What is the recommended dose of IBRANCE for patients with hepatic impairment?No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B). For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. It is recommended to review the Full Prescribing Information for the aromatase inhibitor or fulvestrant for dose modifications related to hepatic impairment.
What are the pharmacokinetic changes observed in patients with hepatic impairment?Based on a pharmacokinetic trial in subjects with varying degrees of hepatic function, the palbociclib unbound exposure (unbound AUCINF) decreased by 17% in subjects with mild hepatic impairment (Child-Pugh class A), and increased by 34% and 77% in subjects with moderate (Child-Pugh class B) and severe (Child-Pugh class C) hepatic impairment, respectively, relative to subjects with normal hepatic function. Peak palbociclib unbound exposure (unbound Cmax) increased by 7%, 38% and 72% for mild, moderate and severe hepatic impairment, respectively, relative to subjects with normal hepatic function.
Is dose adjustment required in patients with renal impairment?No dose adjustment is required in patients with mild, moderate, or severe renal impairment (CrCl >15 mL/min). However, the pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis.
What are the pharmacokinetic changes observed in patients with renal impairment?Based on a pharmacokinetic trial in subjects with varying degrees of renal function, the total palbociclib exposure (AUCINF) increased by 39%, 42%, and 31% with mild (60 mL/min ≤ CrCl <90 mL/min), moderate (30 mL/min ≤ CrCl <60 mL/min), and severe (CrCl <30 mL/min) renal impairment, respectively, relative to subjects with normal renal function. Peak palbociclib exposure (Cmax) increased by 17%, 12%, and 15% for mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function.
FAQ Data Source